- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
BrightInsight Launches Digital Disease Management Solution
BrightInsight, Inc. announced at BIO 2022 the launch of its Disease Management Solution. The Disease Management Solution engages patients and healthcare providers, focusing on improving outcomes, and accelerate time to market for digital health solutions. Biopharma and medtech companies can configure the digital solution to develop offerings to transform how patients manage their health conditions. Their clients can harness real-world data to demonstrate treatment value to differentiate their therapies and ultimately increase their revenue. Industry observers predict that prescribed drugs will decline as personalized and precision treatments with digital components and on-pharmaceutical digital therapeutics will transform the biopharma market. Leveraging data and digital components in the biopharma industry will help with aiming to improve therapy adherence and enhance the patients care experience.
Read more about this news release here.
Inside an Individual’s Physiological Signature
January 15th 2023John Varaklis, chief strategy officer for PhysIQ, discusses the company's machine-learning based algorithms for the detection and early detection of physiological conditions to inform both clinical care and clinical drug development.
